Report cover image

Global Epidermolysis Bullosa Therapeutics Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 105 Pages
SKU # APRC20103163

Description

Summary

According to APO Research, The global Epidermolysis Bullosa Therapeutics market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Epidermolysis Bullosa Therapeutics include Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc. and Stratatech Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Epidermolysis Bullosa Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermolysis Bullosa Therapeutics.

The Epidermolysis Bullosa Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Epidermolysis Bullosa Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Epidermolysis Bullosa Therapeutics Segment by Company

Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.

Epidermolysis Bullosa Therapeutics Segment by Type

INM-750
ICX-RHY
FCX-007
EB-201
Others

Epidermolysis Bullosa Therapeutics Segment by Application

Clinic
Hospital
Others

Epidermolysis Bullosa Therapeutics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epidermolysis Bullosa Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epidermolysis Bullosa Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epidermolysis Bullosa Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epidermolysis Bullosa Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Epidermolysis Bullosa Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

105 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Epidermolysis Bullosa Therapeutics Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Epidermolysis Bullosa Therapeutics Sales Estimates and Forecasts (2020-2031)
1.3 Epidermolysis Bullosa Therapeutics Market by Type
1.3.1 INM-750
1.3.2 ICX-RHY
1.3.3 FCX-007
1.3.4 EB-201
1.3.5 Others
1.4 Global Epidermolysis Bullosa Therapeutics Market Size by Type
1.4.1 Global Epidermolysis Bullosa Therapeutics Market Size Overview by Type (2020-2031)
1.4.2 Global Epidermolysis Bullosa Therapeutics Historic Market Size Review by Type (2020-2025)
1.4.3 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Epidermolysis Bullosa Therapeutics Sales Breakdown by Type (2020-2025)
1.5.2 Europe Epidermolysis Bullosa Therapeutics Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales Breakdown by Type (2020-2025)
1.5.4 South America Epidermolysis Bullosa Therapeutics Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Epidermolysis Bullosa Therapeutics Industry Trends
2.2 Epidermolysis Bullosa Therapeutics Industry Drivers
2.3 Epidermolysis Bullosa Therapeutics Industry Opportunities and Challenges
2.4 Epidermolysis Bullosa Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Epidermolysis Bullosa Therapeutics Revenue (2020-2025)
3.2 Global Top Players by Epidermolysis Bullosa Therapeutics Sales (2020-2025)
3.3 Global Top Players by Epidermolysis Bullosa Therapeutics Price (2020-2025)
3.4 Global Epidermolysis Bullosa Therapeutics Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Epidermolysis Bullosa Therapeutics Major Company Production Sites & Headquarters
3.6 Global Epidermolysis Bullosa Therapeutics Company, Product Type & Application
3.7 Global Epidermolysis Bullosa Therapeutics Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Epidermolysis Bullosa Therapeutics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Epidermolysis Bullosa Therapeutics Players Market Share by Revenue in 2024
3.8.3 2023 Epidermolysis Bullosa Therapeutics Tier 1, Tier 2, and Tier 3
4 Epidermolysis Bullosa Therapeutics Regional Status and Outlook
4.1 Global Epidermolysis Bullosa Therapeutics Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Epidermolysis Bullosa Therapeutics Historic Market Size by Region
4.2.1 Global Epidermolysis Bullosa Therapeutics Sales in Volume by Region (2020-2025)
4.2.2 Global Epidermolysis Bullosa Therapeutics Sales in Value by Region (2020-2025)
4.2.3 Global Epidermolysis Bullosa Therapeutics Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Region
4.3.1 Global Epidermolysis Bullosa Therapeutics Sales in Volume by Region (2026-2031)
4.3.2 Global Epidermolysis Bullosa Therapeutics Sales in Value by Region (2026-2031)
4.3.3 Global Epidermolysis Bullosa Therapeutics Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Epidermolysis Bullosa Therapeutics by Application
5.1 Epidermolysis Bullosa Therapeutics Market by Application
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Others
5.2 Global Epidermolysis Bullosa Therapeutics Market Size by Application
5.2.1 Global Epidermolysis Bullosa Therapeutics Market Size Overview by Application (2020-2031)
5.2.2 Global Epidermolysis Bullosa Therapeutics Historic Market Size Review by Application (2020-2025)
5.2.3 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Epidermolysis Bullosa Therapeutics Sales Breakdown by Application (2020-2025)
5.3.2 Europe Epidermolysis Bullosa Therapeutics Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales Breakdown by Application (2020-2025)
5.3.4 South America Epidermolysis Bullosa Therapeutics Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Birken AG
6.1.1 Birken AG Comapny Information
6.1.2 Birken AG Business Overview
6.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolio
6.1.5 Birken AG Recent Developments
6.2 Fibrocell Science, Inc.
6.2.1 Fibrocell Science, Inc. Comapny Information
6.2.2 Fibrocell Science, Inc. Business Overview
6.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.2.5 Fibrocell Science, Inc. Recent Developments
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Comapny Information
6.3.2 GlaxoSmithKline Plc Business Overview
6.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments
6.4 InMed Pharmaceuticals Inc.
6.4.1 InMed Pharmaceuticals Inc. Comapny Information
6.4.2 InMed Pharmaceuticals Inc. Business Overview
6.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.4.5 InMed Pharmaceuticals Inc. Recent Developments
6.5 Karus Therapeutics Limited
6.5.1 Karus Therapeutics Limited Comapny Information
6.5.2 Karus Therapeutics Limited Business Overview
6.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolio
6.5.5 Karus Therapeutics Limited Recent Developments
6.6 ProQR Therapeutics N.V.
6.6.1 ProQR Therapeutics N.V. Comapny Information
6.6.2 ProQR Therapeutics N.V. Business Overview
6.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolio
6.6.5 ProQR Therapeutics N.V. Recent Developments
6.7 RegeneRx Biopharmaceuticals, Inc.
6.7.1 RegeneRx Biopharmaceuticals, Inc. Comapny Information
6.7.2 RegeneRx Biopharmaceuticals, Inc. Business Overview
6.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Developments
6.8 Scioderm, Inc.
6.8.1 Scioderm, Inc. Comapny Information
6.8.2 Scioderm, Inc. Business Overview
6.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.8.5 Scioderm, Inc. Recent Developments
6.9 Stratatech Corporation
6.9.1 Stratatech Corporation Comapny Information
6.9.2 Stratatech Corporation Business Overview
6.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolio
6.9.5 Stratatech Corporation Recent Developments
6.10 TWi Pharmaceuticals, Inc.
6.10.1 TWi Pharmaceuticals, Inc. Comapny Information
6.10.2 TWi Pharmaceuticals, Inc. Business Overview
6.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.10.5 TWi Pharmaceuticals, Inc. Recent Developments
6.11 WAVE Life Sciences Ltd.
6.11.1 WAVE Life Sciences Ltd. Comapny Information
6.11.2 WAVE Life Sciences Ltd. Business Overview
6.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolio
6.11.5 WAVE Life Sciences Ltd. Recent Developments
7 North America by Country
7.1 North America Epidermolysis Bullosa Therapeutics Sales by Country
7.1.1 North America Epidermolysis Bullosa Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
7.1.3 North America Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031)
7.2 North America Epidermolysis Bullosa Therapeutics Market Size by Country
7.2.1 North America Epidermolysis Bullosa Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Epidermolysis Bullosa Therapeutics Market Size by Country (2020-2025)
7.2.3 North America Epidermolysis Bullosa Therapeutics Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Epidermolysis Bullosa Therapeutics Sales by Country
8.1.1 Europe Epidermolysis Bullosa Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
8.1.3 Europe Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031)
8.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Country
8.2.1 Europe Epidermolysis Bullosa Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2020-2025)
8.2.3 Europe Epidermolysis Bullosa Therapeutics Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales by Country
9.1.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
9.1.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Country
9.2.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Epidermolysis Bullosa Therapeutics Sales by Country
10.1.1 South America Epidermolysis Bullosa Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
10.1.3 South America Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031)
10.2 South America Epidermolysis Bullosa Therapeutics Market Size by Country
10.2.1 South America Epidermolysis Bullosa Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Epidermolysis Bullosa Therapeutics Market Size by Country (2020-2025)
10.2.3 South America Epidermolysis Bullosa Therapeutics Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country
11.1.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
11.1.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country
11.2.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Epidermolysis Bullosa Therapeutics Value Chain Analysis
12.1.1 Epidermolysis Bullosa Therapeutics Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Epidermolysis Bullosa Therapeutics Production Mode & Process
12.2 Epidermolysis Bullosa Therapeutics Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Epidermolysis Bullosa Therapeutics Distributors
12.2.3 Epidermolysis Bullosa Therapeutics Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.